The sore area tells the clinician where to begin

Orthobiologics are shots prepared from blood or marrow

Orthobiologics refers to shots using a person's blood or marrow. The clinician puts the shot in an aching joint or tendon. The name doesn't tell you which kind someone is offering.

Clinics call one blood choice PRP, or platelet-rich plasma, the pale liquid saved when clinic equipment spins your drawn blood. Spinning separates the blood and leaves liquid with more platelets. Platelets are tiny blood parts that make a plug and begin repair after injury. Concentrated PRP means that liquid has a higher amount of platelets.

Another choice is bone-marrow concentrate, made when a needle draws marrow near the pelvis and a machine spins it. Marrow is the soft tissue inside your bones. The machine keeps a smaller portion for the shot. That collection requires a needle into bone, making it different from a blood draw.

A knee study reports what happened to knees in that study. It doesn't prove the same shot will help a shoulder or hip. The shot and the sore tissue must match.

A regenerative treatment uses blood or marrow to prepare the shot

The exam starts with how the joint behaves during your usual day. The clinician checks movement, strength, sore spots, and nearby nerves. A past diagnosis or X-ray can add helpful facts. More basic care may make sense before a shot.

After that exam, QC Kinetix may discuss regenerative care, meaning a non-surgical shot using your blood or marrow. Medical providers are clinic staff trained to check the sore area and explain care. They'll name the likely source of soreness and the spot for the shot. They'll also explain how long normal activity may be limited.

Home care still matters while you consider the choice. Keep daily activity fairly steady instead of making large changes. Note whether the soreness lasts minutes, hours, or into the next morning. Your notes show exactly what the joint can handle.

Learn the cause first, then ask whether a blood-based or marrow-based shot may help.

Sources

1. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.

2. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

4. A network meta-analysis of 11 RCTs (1,353 patients) with HIP osteoarthritis found that at 2-4 and 6 months NO intervention - corticosteroid, hyaluronic acid or PRP - significantly outperformed intra-articular saline placebo for either pain or function, while all interventions including placebo produced improvement exceeding the minimal clinically important difference from baseline. Evidence from the knee does not transfer to the hip.

   Gazendam A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.

5. A meta-analysis with meta-regression of 10 Level I-II studies (696 patients) of PRP augmentation during rotator cuff repair classified trials by whether the platelet concentration factor exceeded a 4-fold increase over whole blood. Neither patient-reported outcomes nor retear rates differed between high-dose and low-dose PRP - a direct test of the 'more platelets is better' premise, which it did not support in this setting.

   Lim JJ, et al. — Platelet Concentration Does Not Influence Clinical Efficacy and Retear Rates of Rotator Cuff Repair With Platelet-Rich Plasma: A Systematic Review and Meta-analysis With Meta-Regression.. American Journal of Sports Medicine, 2026. DOI: 10.1177/03635465261434001.

6. A multicenter prospective crossover randomized trial randomised 40 patients with discogenic chronic low back pain to a saline trigger-point control, intradiscal PRP, or intradiscal bone marrow concentrate, with crossover permitted for non-responders. Both PRP and BMC produced statistically significant improvement in pain and function with no adverse events, hospitalisations or surgery at 12 months - but ALL placebo patients reported under 50% relief and crossed over, and the trial was small and open-label.

   Navani A, et al. — The Safety and Effectiveness of Orthobiologic Injections for Discogenic Chronic Low Back Pain: A Multicenter Prospective, Crossover, Randomized Controlled Trial with 12 Months Follow-up.. Pain Physician, 2024.

7. The AAOS patient-education FAQ on orthobiologics states that because orthobiologics are relatively new the evidence supporting their use is LIMITED, that rigorous testing of effectiveness in most orthopedic conditions is lacking, and that preliminary results are encouraging but hard to evaluate. It names tendinopathies such as tennis elbow, pain from early knee osteoarthritis, adjunct healing after rotator cuff repair, and avascular necrosis as the settings where biologic therapies have shown promise, and notes that stem cell treatments not derived from the patient's own body and further manipulated in a laboratory can only be offered inside an FDA-approved clinical trial.

   American Academy of Orthopaedic Surgeons — Orthobiologics (Regenerative Medicine) FAQ. OrthoInfo (AAOS), 2024.

8. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.